Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: A single-center experience

International Journal of Urology

Volumn 17, Issue 11, 2010, Pages 950-955

  Okegawa, Takatsugu ^a   Nutahara, Kikuo ^a   Higashihara, Eiji ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

Alternative antiandrogen; Antiandrogen withdrawal syndrome; Castration resistant prostate cancer; Maximum androgen blockade

Indexed keywords

BICALUTAMIDE; CHLORMADINONE ACETATE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CASTRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; CHLORMADINONE ACETATE; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NITRILES; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TOSYL COMPOUNDS; TREATMENT FAILURE;

EID: 77958608337     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02620.x     Document Type: Article

References (14)

1. Scher HI, Liebertz C, Kelly WK et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J. Clin. Oncol. 1997; 15: 2928-38.
2. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology 1996; 47: 61-9.
3. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J. Urol. 2006; 175: 27-34.
4. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46: 142-8.
5. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G. High dose BCL for androgen independent prostate cancer: effect of prior hormonal therapy. J. Urol. 1998; 159: 149-53.
6. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J. Urol. 2004; 171: 679-83.
7. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int. 2005; 96: 791-5.
8. Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int. J. Urol. 2007; 14: 264-7.
9. Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A, Miki T, Kyoto Prefectural University of Medicine Prostate Cancer Research Group. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int. J. Urol. 2007; 14: 128-32.
10. Suzuki H, Okihara K, Miyake H et al. Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J. Urol. 2008; 180: 921-7.
11. Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 2004; 22: 537-56.
12. Armstrong AJ, Garret-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 2007; 25: 3965-70.
13. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declined for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 2006; 98: 516-21.
14. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int. 2001; 87: 806-13.